COMMUNIQUÉS West-GlobeNewswire

Ipsen fait le point sur l'essai de Phase II FALKON chez les patients atteints d’une maladie osseuse ultra-rare, la fibrodysplasie ossifiante progressive (FOP)
19/12/2025
PARIS, FRANCE – 19 décembre 2025 – Ipsen (Euronext : IPN ; ADR : IPSEY) annonce aujourd'hui que l'essai pivotal de Phase II FALKON n'a pas atteint son critère principal, à savoir la réduction du volume de formation [...]
Ipsen update on Phase II FALKON trial in patients with ultra-rare bone disease, fibrodysplasia ossificans progressiva (FOP)
19/12/2025
PARIS, FRANCE, 19 December 2025 - Ipsen (Euronext: IPN; ADR: IPSEY) today announced that the pivotal Phase II FALKON trial did not meet its primary endpoint of reducing new heterotopic ossification (HO) in adults and [...]
Fagron accelerates global expansion with two strategic acquisitions and a key North American licensing milestone
19/12/2025
Regulated information - inside information Nazareth (Belgium)/Rotterdam (The Netherlands), 19 December 2025 – 7:00 AM CET Fagron accelerates global expansion with two strategic acquisitions and a key North American [...]
Avec l’acquisition d’ORA, IBA renforce son leadership stratégique en médecine nucléaire
19/12/2025
Louvain-la-Neuve, Belgique, le 19 décembre 2025 - IBA (Ion Beam Applications S.A., EURONEXT), leader mondial des technologies d’accélération de particules et acteur de premier plan en médecine nucléaire, acquiert ORA, [...]
IBA acquires ORA expanding its strategic leadership in Nuclear Medicine
19/12/2025
Louvain-La-Neuve, Belgium, 19 December 2025 - IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology with a preeminent position in nuclear medicine, acquires ORA, a global [...]
DXS INTERNATIONAL PLC (AQSE: DXSP) Result of AGM
19/12/2025
19 December 2025 DXS INTERNATIONAL PLC (AQSE: DXSP) Result of DXS AGM 2025 The Board of DXS International plc (“the Company” or “DXSP”), the AQSE Growth Market quoted healthcare information and digital clinical decision [...]
Genenta Science Provides Update on CEO Ownership
19/12/2025
MILAN and NEW YORK, Dec. 19, 2025 (GLOBE NEWSWIRE) -- Genenta Science (Nasdaq: GNTA), a clinical-stage gene-therapy company developing hematopoietic stem-cell-based immunotherapies for solid tumors, provides an update [...]
Sai Life Sciences Releases Sustainability Report 2024–25
19/12/2025
HYDERABAD, India, Dec. 19, 2025 (GLOBE NEWSWIRE) -- Sai Life Sciences Limited (BSE: 544306 | NSE: SAILIFE), one of India’s fastest-growing Contract Research, Development, and Manufacturing Organizations (CRDMO) , today [...]
GUERBET: Nomination de M. François Convenant en tant que Senior Vice-Président Radiologie Interventionnelle et son entrée au Comité Exécutif
19/12/2025
Guerbet annonce la nomination de M. François Convenant en tant que Senior Vice-Président Radiologie Interventionnelle et son entrée au Comité Exécutif Villepinte, le 19 décembre 2025 : GUERBET (FR0000032526 GBT), acteur [...]
Guerbet: Appointment of Mr. François Convenant as Senior Vice President of Interventional Radiology and his entry into the Executive Committee
19/12/2025
Guerbet announces the appointment of Mr. François Convenant as Senior Vice President of Interventional Radiology and his entry into the Executive Committee Villepinte, December 19, 2025: GUERBET (FR0000032526 GBT), a [...]
Alvotech and Teva Secure U.S. Settlement Date for AVT06, a Proposed Biosimilar to Eylea®
19/12/2025
According to the settlement agreement, the proposed biosimilar to Eylea® (aflibercept) can be marketed in the U . S . , if approved by the FDA, in the fourth quarter of 2026 , or earlier under certain circumstances [...]
Alvotech and Teva Secure U.S. Settlement Date for AVT06, a Proposed Biosimilar to Eylea®
19/12/2025
According to the settlement agreement, the proposed biosimilar to Eylea® (aflibercept) can be marketed in the U.S., if approved by the FDA, in the fourth quarter of 2026, or earlier under certain circumstances REYKJAVIK [...]
Alvotech and Teva Secure U.S. Settlement Date for AVT06, a Proposed Biosimilar to Eylea®
19/12/2025
According to the settlement agreement, the proposed biosimilar to Eylea ® (aflibercept) can be marketed in the U.S., if approved by the FDA, in the fourth quarter of 2026, or earlier under certain circumstances [...]
Mesa Labs to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026
19/12/2025
LAKEWOOD, Colo., Dec. 18, 2025 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc. (NASDAQ:MLAB), a global leader in the design and manufacture of life science tools and critical quality control solutions, today announced that [...]
Is SkinnyRx the Best GLP-1 Vendor for 2026? Platform Offers Compounded Semaglutide in Three Forms Starting at $199/Month as New Year Weight Loss Season Approaches
19/12/2025
Sacramento Telehealth Company Positions Multi-Form Compounded Semaglutide Access Through Licensed Medical Providers Ahead of Peak January Demand Period Sacramento, Dec. 18, 2025 (GLOBE NEWSWIRE) -- With the New Year [...]
Rezubio Announces $20 Million Series A Financing to Advance the Membrane-Anchored Therapeutics Platform and Company Pipeline, with Lead Program in Obesity and Diabetes
19/12/2025
ZHUHAI, China, Dec. 18, 2025 (GLOBE NEWSWIRE) -- Rezubio, a China-based biotechnology company founded by former Merck scientists, today announced the closing of a $20 million Series A financing. Proceeds will be used to [...]
Talkspace Releases Family Guide on Why Stress Spikes in December, and How to Break the Cycle
18/12/2025
Therapists say academic and holiday pressures exacerbate teens’ stress levels, and there are steps parents can take to help. New York, NY , Dec. 18, 2025 (GLOBE NEWSWIRE) -- Talkspace has released a seasonal guide to [...]
Galapagos Announces Topline Results from Two Phase 3-Enabling Studies with Selective TYK2 Inhibitor GLPG3667 in Dermatomyositis and Systemic Lupus Erythematosus
18/12/2025
GLPG3667 met primary endpoint in dermatomyositis study, demonstrating a statistically significant clinical benefit and meaningful improvements on secondary measures of disease activity compared to placebo In the [...]
Cue Biopharma Announces Proposed Public Offering
18/12/2025
BOSTON, Dec. 18, 2025 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate disease- [...]

Pages